Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Atack

Showing results (91-100 of 97) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 97 results.
Journal of Medicinal Chemistry|November 11, 2005
7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal modelsRobert W Carling, Andrew Madin, Alec Guiblin, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 26, 2009
Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humansJohn R Atack, Dean F Wong, Tim D Fryer, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical developmentMichael A Letavic, Leah Aluisio, John R Atack, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 18, 2005
Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepinesRebecca Dias, Wayne F A Sheppard, Rosa L Fradley, et al.
Journal of Medicinal Chemistry|December 23, 2024
Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X SyndromeAlex G Baldwin, David W Foley, Ross Collins, et al.
Journal of Medicinal Chemistry|February 17, 2006
Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxietyMichael G N Russell, Robert W Carling, Leslie J Street, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 26, 2009
In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonistJohn R Atack, Karen A Maubach, Keith A Wafford, et al.
Pageof 10

Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
Journal of Medicinal Chemistry|November 11, 2005
7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal modelsRobert W Carling, Andrew Madin, Alec Guiblin, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 26, 2009
Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humansJohn R Atack, Dean F Wong, Tim D Fryer, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical developmentMichael A Letavic, Leah Aluisio, John R Atack, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 18, 2005
Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepinesRebecca Dias, Wayne F A Sheppard, Rosa L Fradley, et al.
Journal of Medicinal Chemistry|December 23, 2024
Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X SyndromeAlex G Baldwin, David W Foley, Ross Collins, et al.
Journal of Medicinal Chemistry|February 17, 2006
Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxietyMichael G N Russell, Robert W Carling, Leslie J Street, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 26, 2009
In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonistJohn R Atack, Karen A Maubach, Keith A Wafford, et al.
Pageof 10